A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity. METHODS: In this randomized, double-blind trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we enrolled adolescents (12 to <18 years of age) with obesity and a poor response to lifestyle therapy alone. Participants were randomly assigned (1:1) to receive either liraglutide (3.0 mg) or placebo subcutaneously once daily, in addition to lifestyle therapy. The primary end point was the change from baseline in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) standard-deviation score at week 56. RESULTS: A total of 125 participants were assigned to the liraglutide group and 126 to the placebo group. Liraglutide was superior to placebo with regard to the change from baseline in the BMI standard-deviation score at week 56 (estimated difference, -0.22; 95% confidence interval [CI], -0.37 to -0.08; P = 0.002). A reduction in BMI of at least 5% was observed in 51 of 113 participants in the liraglutide group and in 20 of 105 participants in the placebo group (estimated percentage, 43.3% vs. 18.7%), and a reduction in BMI of at least 10% was observed in 33 and 9, respectively (estimated percentage, 26.1% vs. 8.1%). A greater reduction was observed with liraglutide than with placebo for BMI (estimated difference, -4.64 percentage points) and for body weight (estimated difference, -4.50 kg [for absolute change] and -5.01 percentage points [for relative change]). After discontinuation, a greater increase in the BMI standard-deviation score was observed with liraglutide than with placebo (estimated difference, 0.15; 95% CI, 0.07 to 0.23). More participants in the liraglutide group than in the placebo group had gastrointestinal adverse events (81 of 125 [64.8%] vs. 46 of 126 [36.5%]) and adverse events that led to discontinuation of the trial treatment (13 [10.4%] vs. 0). Few participants in either group had serious adverse events (3 [2.4%] vs. 5 [4.0%]). One suicide, which occurred in the liraglutide group, was assessed by the investigator as unlikely to be related to the trial treatment. CONCLUSIONS: In adolescents with obesity, the use of liraglutide (3.0 mg) plus lifestyle therapy led to a significantly greater reduction in the BMI standard-deviation score than placebo plus lifestyle therapy. (Funded by Novo Nordisk; NN8022-4180 ClinicalTrials.gov number, NCT02918279.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In adolescents with obesity, liraglutide 3.0 mg reduced BMI by 4.3% over 56 weeks compared to 0.3% with placebo, with early treatment response predicting long-term effectiveness.39”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [39]
In the citing paper
“but modest reduction in main CVD factors over 56 weeks of treatment.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [112]
In the citing paper
“In a key RCT, there were notable reductions in BMI SDS and higher percentages of participants achieving ≥ 5% and ≥ 10% Weight loss compared to placebo and the BMI standard-deviation score at week 56 (estimated difference, − 0.22; 95% confidence interval [CI], − 0.37 to − 0.08; P = 0.002) [112]”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [112]
In the citing paper
“Approved by FDA/EMA from age 6.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [112]
In the citing paper
“The liraglutidetreated group demonstrated a placebo-subtracted weight reduction of 5% (29).”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [29]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Establishing a standard definition for child overweight and obesity worldwide: international survey
Cole, T. J. (2000) · BMJ · doi:10.1136/bmj.320.7244.1240 · Cited by 16,480
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Bray, G. A., Kim, K. K., Wilding, J. P. H., & on behalf of the World Obesity Federation (2017) · Obesity Reviews · doi:10.1111/obr.12551 · Cited by 1,612
Freedman, D. S., Mei, Z., Srinivasan, S. R., Berenson, G. S., & Dietz, W. H. (2007) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.08.042 · Cited by 1,562
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
Research works printed but not linked: 1
- Frelut M-L De Filippo G. Drug treatment of child and adolescent obesity. In: Frelut M-L ed. ECOG eBook on child and adolescent obesity. 2015 (https://ebook.ecog-obesity.eu/chapter-treatment/drug-treatment-of-child-and-adolescent-obesity/).
Cited by
Items 301–400 of 720
Obesity management in the pediatric patient
Matson, K. L., & Fenn, N. E. (2024) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxae236 · Cited by 10
Šket, R., Slapnik, B., Kotnik, P., Črepinšek, K., Kern, B. Č., Tesovnik, T., Bizjan, B. J., Vrhovšek, B., Remec, Ž. I., Debeljak, M., et al. (2024) · Advances in Therapy · doi:10.1007/s12325-024-03057-8 · Cited by 13
Focus on Glucagon-like Peptide-1 Target: Drugs Approved or Designed to Treat Obesity
Zhang, J., Wei, J., Lai, W., Sun, J., Bai, Y., Cao, H., Guo, J., & Su, Z. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041651 · Cited by 9
“In 2014, Liraglutide 3mg became the first GLP-1-based anti-obesity medications (AOMs) to be introduced to the U.S. market for the treatment of adult obesity and was approved in 2020 for weight management in adolescents with obesity ages 12 and older [33].”
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Shalitin, S., Phillip, M., & Yackobovitch‐Gavan, M. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01801-w · Cited by 8
“This pattern aligns with prior observations [22, 23].”
Hagenaars, L. L., Bero, L. A., van der Voorn, B., & Schmidt, L. A. (2025) · BMJ · doi:10.1136/bmj-2025-084760 · Cited by 7
“7 Theadolescentrecommendationfordrugtreatmentisbasedonone NovoNordiskfundedtrialofliraglutide(aGLP-1receptoragonist), 26 called the “key reference,” and a Vivus funded trial of phentermine-topiramate (not a GLP-1).”
12-month outcomes of GLP - 1 in severe pediatric obesity: real-world data
Cominato, L., Resende, M. L., Bernardes, N., Rachid, L. L., Passone, C., Mattar, L. B. F., Neme, G., de Souza, S. F. L., dos Santos, C. R. P., Franco, R. R., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1663499 · Cited by 10
Updates on Anti-Obesity Medications in Children and Adolescents
Salama, M., Hassan, D., & Kumar, S. (2025) · Children · doi:10.3390/children12101390 · Cited by 10
“A key issue with GLP-1 receptor agonists is weight regain and reversal of improvements in cardiometabolic risk factors after discontinuation of these medications [50,81,82].”
InfluentialKolli, R. T., Aoutla, S., Jyothi, N., Mohamed Kalifa, M. R. H., Raju, A., & Cheenikkal Muralidharan, K. (2025) · Cureus · doi:10.7759/cureus.94926 · Cited by 7
Zhou, L., Wei, A., Pan, C., Zhang, J., Hu, P., Li, X., Zhao, X., Hu, Y., He, B., Liu, Y., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09950-4 · Cited by 11
Puri, K., Adachi, I., Bocchini, C. E., Spinner, J. A., Denfield, S. W., Sisley, S. R., Elias, B. A., Jimenez-Gomez, A., Price, J. F., Dreyer, W. J., et al. (2021) · ASAIO Journal · doi:10.1097/mat.0000000000001633 · Cited by 7
As, A., Шохин, И. Е., Rogozhina, E. A., Геннадьевна, Б. Т., Nevretdinova, M. E., Bely, P. A., Zaslavskaya, K. Y., Куркин, Д. В., Koryanova, K. N., Mishchenko, E. S., et al. (2023) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2023-11-3-255-276 · Cited by 9
Effective and appropriate use of weight loss medication in pediatric obesity: a narrative review
Chung, L. Y. (2024) · Journal of Yeungnam Medical Science · doi:10.12701/jyms.2024.00353 · Cited by 7
“A recent study confirmed the effectiveness of lira-glutide in children and adolescents who were obese and not responsive to lifestyle therapy [33].”
BackgroundPediatric obesity: a mini-review for pediatrician.
Brambilla, I., Bellanca, E., Pistone, C., Filippo, M. D., Votto, M., Tondina, E., Licari, A., Guarracino, C., & Marseglia, G. L. (2022) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v93is3.13078 · Cited by 11
“In a 2020 trial, the use of liraglutide plus lifestyle therapy led to a significant reduction of BMI in obese adolescents (27).”
MethodFloegel‐Shetty, A. (2023) · The AMA Journal of Ethic · doi:10.1001/amajethics.2023.478 · Cited by 6
Wu, W., Zheng, J., Wang, R., & Wang, Y. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115863 · Cited by 9
Scoping review of obesity interventions: Research frontiers and publication status
Zhang, L., Dai, S., Chen, Y. A., Jin, T., Li, W., Wang, W., Pu, J. Y., Jia, P., Zhao, L., & Sun, X. (2024) · iScience · doi:10.1016/j.isci.2024.109240 · Cited by 8
Dillard, J. R., Newsome, F. A., Kelly, A. S., Gross, A. C., Morgan‐Daniel, J., Adkins, L., Madem, S. S., & Cardel, M. I. (2021) · Current Nutrition Reports · doi:10.1007/s13668-021-00351-7 · Cited by 7
Self-citationReassessing type 2 diabetes in adolescents and its management strategies based on insulin resistance
Jia, Q.-Y., Zhang, Y., Zhang, B., & An, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1377918 · Cited by 11
An open‐label 16‐week study of liraglutide in adolescents with obesity post‐sleeve gastrectomy
Zenno, A., Nwosu, E. E., Fatima, S., Nadler, E. P., Mirza, N. M., Brady, S. M., Turner, S. A., Yang, S. B., Lazareva, J., Te‐Vazquez, J., et al. (2024) · Pediatric Obesity · doi:10.1111/ijpo.13154 · Cited by 9
“23 Finally, <20% BMI reduction at BMI nadir was used to define ‘ sub-optimal initial response ’ to SG based on previous literature on weight loss following MBS in adolescents 24 as well as prior use of this criterion by investigators given some evidence that 20% of total body weight loss is…”
Family meals on prescription as treatment for childhood obesity—a randomized controlled trial
Torstensson, T., Bohlin, A., Almquist‐Tangen, G., Roswall, J., Kindblom, J. M., & Sjögren, L. (2024) · European Journal of Pediatrics · doi:10.1007/s00431-024-05744-8 · Cited by 7
Welling, M. S., van Rossum, E. F. C., & van den Akker, E. L. T. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf004 · Cited by 9
Forcina, G., Filippo, P. D., Biasio, D. D., Cesaro, F. G., Frattolillo, V., Massa, A., Cesare, M. D., Marzuillo, P., del Giudice, E. M., & Sessa, A. D. (2025) · Nutrients · doi:10.3390/nu17182942 · Cited by 14
“However, the most promising pharmacotherapies are glucagon-like peptide-1 (GLP-1) receptor agonists, such as liraglutide and semaglutide [22,23].”
The Influence of GLP-1 Agonists on Human Mesenchymal Stem Cells: A Systematic Review
Weber, L., Sharbabaki, M. H., Fuchs, B., Alberton, P., Giunta, R. E., Mert, S., & Thierfelder, N. (2025) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-11002-7 · Cited by 9
Current and Future Pharmacological Interventions for Acquired Hypothalamic Obesity
Roth, C. L., Doelman-Oldenburger, N. J., & van Santen, H. M. (2026) · Drugs · doi:10.1007/s40265-025-02280-z · Cited by 7
Yodoshi, T., Ollberding, N. J., McNeill, M., Ley, S. L., Kirk, S., Kleiner, D. E., Arce‐Clachar, A. C., Bramlage, K., Inge, T. H., Helmrath, M. A., et al. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70766 · Cited by 7
“…in youth with MASLD has been very limited, as the paediatric obesity clinical trials did not specifically assess for presence or severity of MASLD and the mean ALT level was quite low at baseline in trial participants, suggesting a paucity of patients with significant MASLD were enrolled [10, 33].”
Karavia, E. A., Giannopoulou, P. C., Konstantinopoulou, V., Athanasopoulou, K., Filippatos, T. D., Panagiotakos, D. B., & Kypreos, K. E. (2023) · Nutrients · doi:10.3390/nu15030606 · Cited by 7
“0 mg) for 56 weeks plus lifestyle therapy led to a significantly greater reduction in the BMI standard deviation score compared to placebo plus lifestyle therapy in adolescents with obesity [32].”
BackgroundGenetics, pharmacotherapy, and dietary interventions in childhood obesity
Son, J. E. (2024) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2024.12861 · Cited by 15
Bomberg, E. M., Clark, J., Rudser, K. D., Gross, A. C., Kelly, A. S., & Fox, C. K. (2024) · Pediatric Obesity · doi:10.1111/ijpo.13143 · Cited by 6
“Of note, we chose to increase the allowable encounter window for later visits as weight loss is generally non-linear (often greater earlier in courses as seen in AOM clinical trials 15 – 17 ), and given the practical consideration that follow-up over time may occur more sporadically.”
Self-citationUse of GLP-1 Receptor Agonists for the Management of Type 1 Diabetes: A Pediatric Perspective
Nevo-Shenker, M., & Shalitin, S. (2024) · Hormone Research in Paediatrics · doi:10.1159/000541228 · Cited by 9
“The RCT published by Kelly et al. [77] showed that liraglutide 3 mg along with lifestyle modi fi cation led to a signi fi - cantly greater decrease in BMI and body weight compared to the placebo group.”
Engineered thumbtack needle for augmented acupuncture therapy
Cai, R., Zhao, S., Lu, Z., You, J., Wang, H., Xie, A., Wang, S., Han, Q., Zhang, Y., Yu, J., et al. (2025) · Cell Biomaterials · doi:10.1016/j.celbio.2024.100002 · Cited by 7
Janson, A., Bohlin, A., Johansson, B., Lycke, S. T., Gauffin, F., & Klaesson, S. (2021) · Obesity Science & Practice · doi:10.1002/osp4.539 · Cited by 6
“Emerging anti‐obesity drugs may become an option for adolescent patients.(9,10) Bariatric surgery is increasingly suggested for adolescents with severe obesity but remains controversial and underutilized.”
BackgroundMak, D., Ryan, K. A., & Han, J. C. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.756593 · Cited by 7
“In other studies of adolescents and adults with and without cardiac dysfunction, increased heart rate was also observed in association with liraglutide treatment (52, 53).”
BackgroundKahhan, N. A., Hossain, J., Lang, J. E., Harrison, C., Canas, J. A., Wysocki, T., Lochrie, A. S., & Balagopal, P. (2021) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2020.0097 · Cited by 7
“…of pharma-cotherapy and lifestyle approaches appear to be crucial in children with advanced degrees of obesity and/or co-morbidities, 9,11,13,20 previous studies have reported beneficial effects of short-term lifestyle changes on various risk factors and/or novel biomarkers of CMD,…”
Talking About Childhood Obesity
Wagner, E. S., Jamil, O. K., & Hodges, B. (2022) · Clinical Pediatrics · doi:10.1177/00099228211070390 · Cited by 6
ZoomForward2022: European Congress on Obesity
Jørgensen, R. M., Bøttger, B., Vestergaard, E. T., Kremke, B., Bahnsen, R. F., Nielsen, B. W., & Bruun, J. M. (2022) · Obesity Facts · doi:10.1159/000524469 · Cited by 8
Bhattarai, H. B., Paudel, B. S., Parajuli, S. R., Dahal, K., Shah, S., Bhattarai, M., Baral, B., Karki, B., Basnet, B., Bhandari, A., et al. (2025) · Medicine · doi:10.1097/md.0000000000046671 · Cited by 5
“[20,22] This highlights the importance of managing these side effects through dose adjustments, patient education, and potentially combining these agents with other medications to mitigate adverse effects.”
Kennedy, C., Moyer, K., & Herdes, R. E. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.11356 · Cited by 8
“60 A survey of pediatric endocrinologists identified gastro-intestinal side effects as the primary reason for treatment discontinuation.”
Current status of Liraglutide delivery systems for the management of type 2 diabetes mellitus
Chatterjee, R., Galave, V. S. B., & Jindal, A. B. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01965-y · Cited by 7
Adherence and Effectiveness of Liraglutide in Adolescents with Obesity
Yaron, S., Arbel, R., Razi, T., & Nemet, D. (2025) · Childhood Obesity · doi:10.1177/21532176251385715 · Cited by 7
Korus, S., Cembrowska-Lech, D., Kłoda, K., & Stachowska, E. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07702-4 · Cited by 8
“This finding suggests that the source of protein (from highly processed foods) has a significant impact on weight control outcomes, possibly due to differences in bioavailability, thermic effect, sodium content, or impact on gut microbiota, which requires further investigation [4, 5].”
Exenatide for obesity in children and adolescents: Systematic review and meta-analysis
李熙鸿, Chen, B., Xiao, D., Zou, Z., & Zhang, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1290184 · Cited by 9
Acute Kidney and Liver Injury Associated With Low-Dose Liraglutide in an Obese Adolescent Patient
Komargodski, R., Wittenberg, A., Bahat, H., & Rachmiel, M. (2024) · PEDIATRICS · doi:10.1542/peds.2023-063719 · Cited by 5
Morandi, A., Umano, G. R., Vania, A., Gugliemi, V., Muscogiuri, G., Maffeis, C., Busetto, L., Buscemi, S., Cherubini, V., Barazzoni, R., et al. (2024) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-024-01678-0 · Cited by 9
Clinician’s Guide for Pediatric Anti-obesity Medications
Dutton, W. P., Paddu, N. U., Braddock, A. S., & Sweeney, B. R. (2024) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2024.07.006 · Cited by 5
Innovative Glucagon-based Therapies for Obesity
Belay, K. E., Jemal, R. H., & Tuyizere, A. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae197 · Cited by 8
Glucagon-Like Peptide-1 Agonist Use in Adults With Congenital Heart Disease
Thapa, R., Lara-Breitinger, K. M., López-Jiménez, F. A., Shama, N., Egbe, A. C., Miranda, W. R., Connolly, H. M., Jain, C. C., Jokhadar, M., Kosec, A. M., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101674 · Cited by 6
Fornari, E., Barbetti, F., Iafusco, D., Lombardo, F., GIUDICE, E. M. D., Rabbone, I., & Mozzillo, E. (2021) · Minerva Pediatrics · doi:10.23736/s2724-5276.21.06530-7 · Cited by 7
Müssener, U., Örn, M., Olbers, T., Löf, M., & Sjögren, L. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-064893 · Cited by 6
Intervention with Therapeutic Agents, Understanding the Path to Remission to Type 2 Diabetes
Hao, S., Umpierrez, G. E., & Vellanki, P. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.07.004 · Cited by 6
Vargas-Vargas, M. A., González-Montoya, M., Torres‐Isidro, O., Garcia‐Berumen, C. I., Ortiz‐Avila, O., Calderón‐Cortés, E., & Cortés‐Rojo, C. (2024) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v13.i2.91478 · Cited by 8
Kelly, A. S., Bahlke, M., Baker, J. L., de Beaufort, C. E., Belin, R. M., Fonseca, H., Hale, P. M., Holm, J., Hsia, D. S., Jastreboff, A. M., et al. (2024) · Pediatric Obesity · doi:10.1111/ijpo.13161 · Cited by 6
“3,5 The advantages of a lifestyle therapy run-in phase must be weighed against the disadvantages.”
Self-citationKidney consequences of obesity
Nehus, E. J., & Mitsnefes, M. M. (2024) · Pediatric Nephrology · doi:10.1007/s00467-024-06623-y · Cited by 6
López, G. P. (2025) · Medicina Clínica · doi:10.1016/j.medcli.2025.107122 · Cited by 5
Sun, J. W., Hernández–Díaz, S., Bourgeois, F. T., Haneuse, S., Brill, G. E., Bateman, B. T., & Huybrechts, K. F. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14237 · Cited by 7
“Number of distinct generic drugs; median (IQR) 2 (1-5) 3 (1-5) −0.”
BackgroundNogueira‐de‐Almeida, C. A., Hirose, T. S., Zorzo, R. A., Vilanova, K. C. M., & Filho, D. R. (2020) · International Journal of Nutrology · doi:10.1055/s-0040-1721663 · Cited by 10
Recent Advances in Anti-Obesity Drugs
Son, J. W. (2022) · Journal of Korean Diabetes · doi:10.4093/jkd.2022.23.2.113 · Cited by 5
Adipositas und Typ-2-Diabetes (Update 2023)
Clodi, M., Toplak, H., Resl, M., Brix, J. M., Leitner, D. R., Harreiter, J., Hoppichler, F., Wascher, T. C., Schindler, K., & Ludvik, B. H. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02184-6 · Cited by 7
“Darüber hinaus ist Liraglutid auch bei Kindern im Alter zwischen 12 und 18 Jahren zur Gewichtsabnahme zugelassen[47].”
BackgroundChildhood Obesity and GLP-1 Receptor Agonists — A Coming of Age?
Barrett, T. G., & Hamilton-Shield, J. P. (2024) · New England Journal of Medicine · doi:10.1056/nejme2410560 · Cited by 5
Srivastava, G., Campbell, S. L., Hill, C. R., Stanley, T. L., Lawson, E. A., Apovian, C. M., Almandoz, J. P., Leggio, L., Lakdawalla, D. N., Dar, M., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.06.015 · Cited by 5
“In a double-blind clinical trial [132], patients using lir-aglutide (3.0 mg) daily lost an average of 5.0% of their body weight over 56 wk, which was signi fi cantly more than the placebo group.”
InfluentialPelizzo, G., Destro, F., Perretta, S., Paraboschi, I., Zappa, M. A., & Pierucci, U. M. (2025) · Obesity Surgery · doi:10.1007/s11695-025-08139-2 · Cited by 7
“GLP-1 analogs like liraglutide (approved in teens in 2020) have shown roughly 10–12% body weight loss in some responders [87].”
Intersection between Eating Disorders and Obesity in Youth: Implications for Treatment
Button, A. M., Persaud, A., Tanner, A. B., Balantekin, K. N., Tanofsky‐Kraff, M., Jebeile, H., & Wilfley, D. E. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00664-6 · Cited by 6
“There are currently 4 U.S. FDA-approved medications for obesity treatment available to adolescents ages 12+: Orlistat [ 85 ], Wegovy [ 86 ], Saxenda [ 87 ], and Qsymia [ 88 ].”
Putri, R. R. (2025) · Frontiers in Pediatrics · doi:10.3389/fped.2025.1675713 · Cited by 8
Noordam, C., Eiholzer, U., Katschnig, C. K., Stasinaki, A., & Dubinski, I. (2025) · Children · doi:10.3390/children12121716 · Cited by 5
“…to that reported by Kelly et al., differences in study design—including the absence of a placebo control—as well as the wide range of treatment durations and the shorter follow-up compared with the pivotal 56-week trial limit direct comparability and the assessment of long-term efficacy [10].”
InfluentialMultidisciplinary care of pediatric obesity and its impact on sleep: a review
Inja, R. R., & Cielo︎, C. M. (2026) · Frontiers in Sleep · doi:10.3389/frsle.2025.1634185 · Cited by 5
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101445 · Cited by 12
“Among adolescents, semaglutide 2.4 mg weekly achieved a 16.1% BMI reduction at 68 weeks ( vs 0.6%), [140] and liraglutide 3.0 mg daily reduced BMI by 4.6% at 56 weeks ( vs a 1.6% increase) [141].”
InfluentialNg, N. B. H., Sng, A. A., & Huang, J. G. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i1.111211 · Cited by 6
Management of Obesity in Psoriasis Consultations
Nicolau, J., López‐Ferrer, A., & de la Cueva, P. (2026) · Dermatology and Therapy · doi:10.1007/s13555-026-01664-7 · Cited by 5
“Furthermore, lira‑ glutide 3 mg reduced the likelihood of patients with prediabetes progressing to diabetes (OR 8.1, 95% CI 2.6–25.3) [37–39].”
InfluentialiCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70167 · Cited by 5
Strathe, A., Bomberg, E. M., Jensch, G., Kildegaard, J., Harder-Lauridsen, N. M., Weghuber, D., & Overgaard, R. V. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70678 · Cited by 4
One anastomosis gastric bypass in children and adolescents: An international expert survey
Kermansaravi, M., Chiappetta, S., Musella, M., Carbajo, M. A., Kassir, R., Chevallier, J., Gawdat, K., Kular, K. S., Prager, G., Weiner, R. A., et al. (2025) · Clinical Obesity · doi:10.1111/cob.70018 · Cited by 4
“There is a growing need to treat severe obesity in children and adolescents and besides pharmacologic 14,15 and endoscopic treatment, 16,17 MBS remains an important treatment option.”
GLP ‐1 Agonists for Pediatric Psychopharmacology: Opportunities and Cautions
Bartkoski, M., Poweleit, E. A., & Stancil, S. L. (2025) · Clinical and Translational Science · doi:10.1111/cts.70262 · Cited by 6
“…in exploratory depression or suicidality safety end-points between placebo and the study drugs, yet these studies excluded those with psychiatric disorders at baseline and may have been underpowered or confounded by multi-site heterogeneity that limited their ability to detect an effect [6, 7].”
Li, Q., Yang, Q., Han, J. D. J., Xiaohan, L. I. U., Fu, J., & Yin, J. (2022) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(22)60196-1 · Cited by 4
Current pharmacotherapy options in pediatric obesity
Malíková, J. K., Hainerová, I. A., & Lebl, J. (2023) · Česko-slovenská pediatrie · doi:10.55095/cspediatrie2023/017 · Cited by 4
Zhang, S., Liu, Z., Zhang, H., Zhou, X., Wang, X., Chen, Y., Miao, X., Zhu, Y., & Jiang, W. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117163 · Cited by 5
Single-Center Experience of Using Liraglutide in Adolescents With Obesity +/- Type 2 Diabetes
Dauleh, H., Pasha, M., Gad, H., Haris, B., Petrovski, G., Afyouni, H., Khalifa, A., Shehzad, S., Amin, R., Chirayath, S., et al. (2024) · Cureus · doi:10.7759/cureus.58720 · Cited by 8
Efficacy of myo‐inositol and zinc on insulin resistance in a paediatric population with obesity
Antoniotti, V., Partenope, C., Solito, A., Mancioppi, V., Baima, J., Medina, F., Dimarakis, S., Agostini, A., Sista, M. T., Monzani, A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16185 · Cited by 6
“Drugs developed for adult obesity have recently been approved, 26,27 whereas a few studies focus on food supplements able to mitigate some metabolic alterations.”
Role of Microneedles for Improved Treatment of Obesity: Progress and Challenges
Chilamakuri, S. N., Manasa, N., Thalla, M., Ravichandiran, V., Lee, Y., Cho, S. M., Jung, H., & Natesan, S. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01115 · Cited by 5
Impact of refitted race‐free eGFR formula on obesity pharmacotherapy options
Orandi, B. J., McLeod, C., Reed, R. D., Kumar, V., Igel, L. I., Aronne, L. J., Cannon, R. M., Lewis, C. E., & Locke, J. E. (2022) · Obesity · doi:10.1002/oby.23542 · Cited by 4
A Study on Weight Loss Cause as per the Side Effect of Liraglutide
Yu, J. S., Lee, J., Lee, S., Cho, J., & Kim, H. (2022) · Cardiovascular Therapeutics · doi:10.1155/2022/5201684 · Cited by 9
“Since previous studies compared the side effects of liraglutide with those of placebo [14, 15], no studies have directly compared the weight loss effect of the drug discontinuation group.”
ResultEffectiveness of liraglutide in the treatment of adolescent obesity
Pons, M. R., Vilar, M. G., Zurita, C. G., Ferrer, M. E. F., Rodríguez, A. P., & Alonso, C. R. (2025) · Anales de Pediatría (English Edition) · doi:10.1016/j.anpede.2025.503856 · Cited by 3
Irfan, Z., Halder, J., Giri, S., Molla, E. A., & Khanam, S. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113102 · Cited by 6
Granados, I., Wolfgang, K. M., Arasteh, K., Viswanathan, K., Snyder, M., Bunnell, H. T., & Phan, T.-L. T. (2026) · Obesity · doi:10.1002/oby.70128 · Cited by 3
Li, H.-Y., Lip, G. Y. H., Chan, T.-K., Yiu, K. H., Tse, H., Martin, C. A., & Chan, Y.-H. W. (2026) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-026-02297-8 · Cited by 6
“The choice of GLP-1 RA type, dosage, and duration will need careful consideration, as weight regain has been observed following the cessation of GLP-1 RA therapy [52 ].”
Ahmed, I. S., Tapponi, S. L., Manaa, H. M., Soltani, A., Hussein, E. S., Parvaresh, F. A., & Hussain, Z. (2026) · Journal of Obesity · doi:10.1155/jobe/6556057 · Cited by 5
Management of Childhood Obesity
Gad, H., Dauleh, H., Mohammed, I., Malik, R. A., & Hussain, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083528 · Cited by 4
Rivas, J. A., Murphy, A. C., Prasad, P., Yahia, M. S., Goitom, S. S., Romero, A. S., Enriquez, C. M., Maes, B. B., Akepati, P. R., Garcia, M. A., et al. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156652 · Cited by 5
Soliman, A. T., Alyafei, F., Khalil, A., Kardousha, A., Ahmed, S., Alaaraj, N., & Hamed, N. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113400 · Cited by 3
Efficacy of Dapagliflozin Combined with Lifestyle Intervention in Obesity Control
Dai, W., & Qiao-lin, P. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/7745873 · Cited by 3
“evaluates the use of dapagliflozin in the treatment of obesity in the middle-aged and elderly [14].”
BackgroundRetractedCurrent options in obesity pharmacotherapy for children and adolescents
Jung, H. W. (2024) · Precision and Future Medicine · doi:10.23838/pfm.2024.00093 · Cited by 3
Obesity in children: inheritance and treatment – state of art 2024
Wójcik, M., & Zachurzok, A. (2024) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2024.144042 · Cited by 6
Raatz, S. J., FREESE, R. L., Jang, S., Kunin‐Batson, A., Gross, A. C., & Bensignor, M. O. (2024) · Childhood Obesity · doi:10.1089/chi.2024.0351 · Cited by 3
Glucagon-like peptide-1 (GLP-1) receptor agonists: applications in childhood diabetes and obesity
Hu, K., & Barrett, T. G. (2025) · Paediatrics and Child Health · doi:10.1016/j.paed.2025.01.003 · Cited by 3
Trends in Glucagon-Like Peptide 1 Receptor Agonists Utilization for Weight Management in Children
Mak, D., Liu, D., Prodhan, P., & Bansal, S. (2025) · Diabetes Technology and Obesity Medicine · doi:10.1089/dtom.2025.0027 · Cited by 3
“8,11 We also examined a subgroup of patients who had been on medication for more than 2 years, accounting for 27.78% of the high-quality dataset.”
InfluentialFaran, M., O’Callaghan, E. K., McKechnie, T., Barlow, K., Kuszaj, O., Tarride, J., Anvari, M., & Doumouras, A. G. (2025) · Obesity Surgery · doi:10.1007/s11695-025-08054-6 · Cited by 4
“Daily subcutaneous 3.0 mg injection of lira-glutide, combined with behavioural interventions, have been shown to lead to substantial weight loss when compared with a placebo group [13, 14].”
InfluentialObesity treatment - overview of pharmacological and surgical methods
Osiak, J., Mikut, K., Wijata, A., & Kędziora–Kornatowska, K. (2022) · Journal of Education Health and Sport · doi:10.12775/jehs.2022.12.07.005 · Cited by 3
Chen, F., Wu, S., Li, D., Dong, J. P., & Huang, X. (2023) · Nutrients · doi:10.3390/nu15061487 · Cited by 3
Back, H.-M., Choi, S.-A., & Kim, M. G. (2023) · Drug Targets and Therapeutics · doi:10.58502/dtt.23.0003 · Cited by 3
Cerroni, C., Steiner, A., Seanez, L., Kwon, S., & Lewis, A. S. (2023) · Neuroscience Letters · doi:10.1016/j.neulet.2023.137299 · Cited by 4
Updates in the Treatment of Pediatric Obesity
Wright, T. F., Rivero, C. M., & Barlow, S. E. (2023) · Current Treatment Options in Pediatrics · doi:10.1007/s40746-023-00270-5 · Cited by 3
“Liraglutide is FDA approved for use in children 12 years of age and older and works by slowing gastric emptying and increasing insulin in response to glucose [15] as well as targeting receptors in the central nervous system to decrease hunger sensations [12].”
Background
Metadata
- Authors
- Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., & Arslanian, S.
- Affiliations
- University of Minnesota (US)
- From the Department of Pediatrics and Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis (A.S.K.); Novo Nordisk, Søborg, Denmark (P.A.); Pediatric Endocrinology, Hospital Ángeles Puebla, Puebla City, Mexico (M.B.-P.); the Department of Pediatrics, Division of Pediatric Endocrinology, Universitair Ziekenhuis Brussel, Brussels (I.G.); Novo Nordisk, Plainsboro, NJ (P.M.H.); the Division of Pediatrics, Department of Clinical Science Intervention and Technology,...
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-05-28
- Volume
- 382
- Issue
- 22
- Pages
- 2117-2128
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3013213902
- Cited by
- 723
- References
- 34
- Citations by year
- 2026: 133 · 2025: 143 · 2024: 149 · 2023: 109 · 2022: 80 · 2021: 80 · 2020: 26
- FWCI
- 44.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion, other-oa)
- Digital Access to Libraries (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- liraglutide, adolescent obesity, childhood obesity, weight management, GLP-1 receptor agonists, lifestyle therapy, body mass index, gastrointestinal adverse effects, drug discontinuation, long-term weight maintenance, drug efficacy
- MeSH terms
- Liraglutide, Healthy Lifestyle, Adolescent, Blood Glucose, Child, Combined Modality Therapy, Double-Blind Method, Female, Gastrointestinal Diseases, Glycated Hemoglobin, Humans, Injections, Subcutaneous, Male, Body Mass Index, Incretins, Pediatric Obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.